------------------------------------------------------------
[link removed]


** New Resources on AVAC.org ([link removed]) and PrEPWatch ([link removed])
------------------------------------------------------------
May 11, 2021

Dear Advocate,

In this round-up of new AVAC resources you’ll find a wide range of new resources:

Understanding the Latest in HIV Prevention Research

In preparation for HIV Vaccine Awareness Day ([link removed]) coming up next week, we hope you’ll register ([link removed]) to join AVAC’s May 13th webinar: HIV Vaccine in the Midst of COVID, at 10 am EDT/ 1600 h Southern Africa/ 1700 h Eastern Africa.

An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP ([link removed]) : In 2020, two large-scale efficacy trials, HPTN 083 & 084, found that a long-acting injectable form of cabotegravir as PrEP provided high levels of protection among people at risk of HIV. That’s truly exciting. There’s also a lot to learn and understand about next steps. What do the trial results explain, what still needs to be explored, and what do advocates think needs to happen next? Check out our primer for what’s known and what’s next for this emerging biomedical HIV prevention strategy.

A webinar: Long-Acting Injectable Cabotegravir for PrEP - Understanding the results and key areas for advocacy ([link removed]) : AVAC’s May 3rd webinar on CAB-LA featured the researchers who led the studies on long-acting injectable PrEP, and advocates who are defining key issues for the introduction of CAB-LA.

Dive into the AMP Trials ([link removed]) : In this episode of Px Pulse, AVACers Jeanne Baron and Daisy Ouya talk to leading bNAb researcher, IAVI’ ([link removed]) s Devin Sok; veteran HIV research advocate Mark Hubbard who served on AMP's protocol team; and a senior member of the HVTN’s community engagement team, a chief explainer of the AMP trails, Gail Broder. Together they explore why these findings point to the need for combination antibodies, the need for a better understanding of the types of HIV that are circulating in a community, the complicated implications of a key lab test, the TZM-bl assay, and more.

Developments in the HIV Prevention Pipeline: PrEP, vaccines and more: Created by AVAC, EATG ([link removed]) , PrEP in Europe ([link removed]) , and PrEPster ([link removed]) , this slide deck ([link removed]) and recorded webinar ([link removed]) offers community educators and advocates a concise summary of existing and future PrEP products, and a community-level perspective on strategic advocacy for PrEP access and uptake.

Watchdogging PEPFAR

PEPFAR Watch ([link removed]) is a new online resource from a collaboration working to hold PEPFAR accountable to communities. The website features reports, news, and resources to support community-led monitoring, a core initiative for accountability in PEPFAR programs. You can also sign up to become members and gain access to webinars, PEPFAR quarterly data and more. The collaboration includes Health ([link removed]) GAP ([link removed]) , AVAC ([link removed]) , TAG ([link removed]) , the O’Neill Institute ([link removed]) , MPa ([link removed]) ct ([link removed]) , the PLUS Coalition ([link removed]) , amfAR ([link removed]) , and CHANGE ([link removed]) . It should be a one stop shop for all the information you need to monitor and influence PEPFAR Country Operational Plans. Find other supportive resources on AVAC’s page: Advocate for Access to
High-Impact Prevention ([link removed]) .


A Spotlight on Equity and Ethics

Make Your Voice Heard: Towards advancing racial equity & diversity in biomedical research ([link removed]) : In response to a call from the NIH for proposals to advance racial equity, diversity, and inclusion within all facets of the biomedical research workforce, and expand research to eliminate or lessen health disparities and inequities, AVAC’s John Meade authored a blog on the major recommendations offered to the NIH from a coalition of 25 HIV research advocate organization.

How can research ethics committees help to strengthen stakeholder engagement in health research in South Africa? An evaluation of REC documents ([link removed]) : This article, co-authored by our CASPR ([link removed]) partners at South Africa’s HIV AIDS Vaccines Ethics Group (HAVEG) and AVAC’s Jess Salzwedel, and published in the South African Journal of Bioethics and Law, recommends research ethics committees (RECs) step up the focus on stakeholder engagement. Researchers working with REC’s should plan for robust stakeholder engagement and REC documentation should be harmonized to reflect this priority.

Advocacy for Vaccine Access

Breaking the Bottlenecks to COVID-19 Vaccine Access ([link removed]) : Ensuring global access to COVID vaccines—and any health commodity—requires a multi-pronged effort to get the right policies in place. This new infographic identifies the multiple factors that contribute to bottlenecks in the global supply of#COVID19 ([link removed]) vaccines and how to address them.


We hope these resources, which cut across issues facing the field, will empower your advocacy where change is both crucial and possible.

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])